Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8029462 | 0.82 | ACHE (0.39) | CES2CES1TAAR1ACHEALDH1A1 | |
| SCHEMBL1042548 | 0.78 | NFE2L2 (0.43) | ACHEALDH1A1ALOX15BCHENFE2L2 | |
| SCHEMBL1041734 | 0.78 | CA2 (0.40) | ALDH1A1 | |
| SCHEMBL1041826 | 0.78 | MAPT (0.39) | ALDH1A1GAA | |
| SCHEMBL1040594 | 0.78 | CYP2A6 (0.45) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1042642 | 0.73 | HTR2A (0.43) | TAAR1ALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL1042989 | 0.71 | CES2 (0.32) | CES2CES1ALDH1A1ERN1 | |
| SCHEMBL1039758 | 0.71 | CES2 (0.36) | CES2CES1ACHEBCHENFE2L2 | |
| SCHEMBL19968584 | 0.71 | CES2 (0.36) | CES2CES1ACHEALDH1A1BCHE | |
| SCHEMBL1041344 | 0.69 | ACHE (0.38) | CES2CES1TAAR1ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915455-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| EP-2272852-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | Sumitomo Chemical Company, Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-06-04 | — | — | US | disclosed |
| US-7482414-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1683802-A1 | TRANSITION METAL COMPLEX LIGAND AND OLEFIN POLYMERIZATION CATALYST CONTAINING TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | CES2 4628/4885CES1 4598/4885TAAR1 1080/4885 |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | CES2 4628/4885CES1 4598/4885TAAR1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.